


PULMONARY

Groundbreaking vaccine trials


 \longrightarrow

Shaping the future of global healthcare

CURRENT CLINICAL TRIALS



CLINICAL TRIALS FRONTIER












Pulmonary

Molecule	Indication	Phase	No. of Sites	No. of Patients
Beclomethasone Dipropionate	Asthma	III	38	1550
Indamet (Indacaterol and Mometasone Furoate)	Asthma	PMS	5	174
Indacaterol, Mometasone Furoate & Glycopyrronium	Asthma	IV	5	186
Glycopyrrolate, Formoterol Fumarate and Budesonide Inhalation	COPD	IV	6	200
Vilanterol, Glycopyrronium and Fluticasone furoate Inhalation	COPD	III	6	220

Advancements in Pulmonary Medicines - Current Clinical Trials

Pulmonary



Conclusion

The landscape of infectious disease prevention is rapidly evolving with ongoing Phase III vaccine trials across various indications. From Hepatitis A to influenza, these trials are essential steps in advancing global public health. The diverse range of vaccines under investigation signifies a concerted effort to combat infectious diseases that pose significant threats to communities worldwide. The outcomes of these trials will not only impact the individuals directly involved but also contribute to the broader mission of creating a healthier and more resilient global population.